🔎 Trials Near Me

Почетна › Sitnoćelijski rak pluća › Тексас

Kliničke studije za Sitnoćelijski rak pluća u državi Тексас

42 studija za Sitnoćelijski rak pluća traži učesnike na lokacijama u državi Тексас.

Gradovi u državi Тексас

Zvanični tekst studije (na engleskom)

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

  • The University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT06805825

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

  • Next Oncology - Austin, Austin
  • Next Oncology - Houston, Houston
  • Next Oncology - Dallas, Irving
  • и још 1
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07488676

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

  • NEXT Dallas, Irving
  • NEXT Oncology, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT03460977

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

  • Texas Oncology - Central/South Texas, Austin
  • Texas Oncology - Northeast Texas, Tyler
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06646276

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

  • GSK Investigational Site, Fort Worth
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07099898

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  • NEXT Oncology, Austin
  • UT Southwestern, Dallas
Тражи се учесникФаза 1
Узраст 19 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06586957

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

  • The University of Texas MD Anderson Cancer Center (site 127), Houston
Тражи се учесникФаза 1/2
Узраст од 18 до 80 · Оба пола · Ажурирано 4. 11. 2026. · NCT03556228

A Study of MGC026 in Participants With Advanced Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
  • University of Texas Health Science Center at Houston, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06242470

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

  • The University of Texas MD Anderson Cancer Center /ID# 277929, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT07155174

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 21. 10. 2026. · NCT07278479

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

  • Research Site 135, Austin
  • Research Site 120, Dallas
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 21. 10. 2026. · NCT05914116

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT07564401

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

  • Avenzo Therapeutics Recruiting Site, Dallas
  • Avenzo Therapeutics Recruiting Site, Houston
  • Avenzo Therapeutics Recruiting Site, San Antonio
Тражи се учесникФаза 1/2
Узраст од 18 до 75 · Оба пола · Ажурирано 16. 10. 2026. · NCT07038343

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

  • UT Southwestern Medical Center, Dallas
  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT07488923

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

  • Texas Oncology - Central South, Austin
  • University of Texas Southwestern Medical Center/Clinical Research Department, Dallas
  • Texas Oncology - West Texas, Odessa
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT07218146

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  • The University of Texas MD Anderson Cancer Center, Houston
  • Texas Oncology Cancer Center, Sugar Land
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT06712355

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

  • Clinical Trial Site, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT07749586

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

  • Texas Oncology - Northeast Texas, Allen
  • Texas Oncology - DFW, Arlington
  • Texas Oncology - DFW, Arlington
  • и још 33
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07226999

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

  • NEXT Oncology, Irving
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT07454642

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • New Experimental Therapeutics - NEXT Oncology, Austin
  • Texas Oncology, Bedford
  • UT Southwest Simmons Cancer Center, Dallas
  • и још 2
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 2. 10. 2026. · NCT04585750

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

  • MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT07189871

DESTINY-PANTUMOUR04

  • Research Site, Dallas
Тражи се учесникОпсервациона студија
Узраст од 18 до 130 · Оба пола · Ажурирано 25. 9. 2026. · NCT07124000

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  • Baylor, Scott and White Research Institute, Dallas
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 24. 9. 2026. · NCT06047379

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

  • The University of Texas MD Anderson Cancer Center /ID# 280070, Houston
  • Texas Oncology - Northeast Texas /ID# 280642, Tyler
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 23. 9. 2026. · NCT07365241

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

  • Oncology Consultants, P.A., Houston
  • University of Texas M.D. Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 21. 9. 2026. · NCT05983432

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

  • Site 1005, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 17. 9. 2026. · NCT07407933

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

  • MD Anderson Cancer Center Uni of Te, Houston
Тражи се учесникФаза 1/2
Узраст од 18 до 100 · Оба пола · Ажурирано 27. 8. 2026. · NCT06726148

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

  • Texas Oncology - DFW, Dallas
  • MD Anderson Cancer Center, Houston
  • Texas Oncology - Northeast, Tyler
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 8. 2026. · NCT06892548

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
  • University of Texas Southwestern Medical Center, Dallas
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 17. 8. 2026. · NCT06095505

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • The University of Texas, MD Anderson Cancer Center, Houston
  • UT Health Mays Cancer Center, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 11. 8. 2026. · NCT05592626

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

  • Houston Methodist Cancer Center, Houston
  • University of Texas Md Anderson Cancer Center, Houston
  • Texas Oncology, P.A. - Tyler, Tyler
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 6. 8. 2026. · NCT06203210

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
  • NEXT Dallas, Irving
  • South Texas Accelerated Research Therapeutics, LLC, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 22. 7. 2026. · NCT06131840

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

  • Mays Cancer Center / University of Texas, San Antonio, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 15. 7. 2026. · NCT05652686

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

  • The University of Texas MD Anderson Cancer Center, Houston
  • Oncology Consultants, PA- Houston, Houston
  • Next Oncology Dallas, Irving
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 9. 7. 2026. · NCT07174583

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

  • University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 26. 6. 2026. · NCT06598306

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

  • START Dallas, Fort Worth
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 6. 2026. · NCT07517198

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

  • NEXT Oncology Austin, Austin
  • NEXT Oncology San Antonio, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 7. 4. 2026. · NCT07424547

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

  • M D Anderson Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 30. 3. 2026. · NCT06769126

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

  • Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 11. 3. 2026. · NCT06681220

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

  • NEXT Oncology - Dallas, Dallas
  • START San Antonio, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 18. 2. 2026. · NCT07030257

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.